MedTrace Logo

Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

NCT02757417 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-05-06

No results posted yet for this study

Summary

To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result in shorter cystoscopy times.

Conditions

  • Ureteral Injury

Interventions

DRUG

sodium fluorescein

DRUG

phenazopyridine

Sponsors & Collaborators

  • Megan Billow

    collaborator UNKNOWN

  • Graham Chapman

    collaborator UNKNOWN

  • Sangeeta Mahajan

    collaborator UNKNOWN

  • Alex Soriano

    collaborator UNKNOWN

  • Sherif El-Nashar

    collaborator UNKNOWN

  • University Hospitals Cleveland Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-01-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02757417 on ClinicalTrials.gov